Study of Cisplatin in Cervical Cancer Stage IVB

Inclusion Criteria: * women with advanced recurrent or persistent carcinoma of the uterine cervical who were unsuitable candidates for curative treatment with surgery and/or radiotherapy. * Histologic types included squamous, adenosquamous, and adenocarcinoma of the cervia. * Patients must be at least 18 years old. * Measurable and/or evaluable disease parameters will be documented and recorded using clinical evaluation (and using CT for pathologic nodes when present). * Life expectation greater than 3 months. * Patients must have adequate organ function. * Patients without history of sensitivity to camptothecin or platinum. * Patients who are non-child-bearing potential, or consistent and correct use of methods of birth control from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of observational medication. * performance status 0 to 2; to have recovered from the effects of recent surgery, chemoradiotherapy, or radiotherapy; and to be free of clinically significant infection. * Written informed consent Exclusion Criteria: * Patients with uncontrolled infections. * Patients with concurrent severe medical problems unrelated to the malignancy which would expose the patient to extreme risk. * Patients who received another investigational drug within 30 days prior to study entry. * Patients who are receiving concurrent other chemotherapy, hormonal, immunotherapy or radiotherapy. Radiotherapy for palliation of related bone metastases is permitted. * Patients with a history of allergic reactions to compounds chemically related to topotecan or platinum. * Patients who are pregnant or lactating * Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin.